|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,929.00 GBX | +0.23% |
|
-1.54% | +5.23% |
| 22/06 | US FDA declines to approve Achieve Life Sciences' smoking-cessation drug | RE |
| 19/06 | FTSE 100 flat as investors weigh US-Iran peace talks, energy stocks support | RE |
| Market Cap | 7.67TCr 10TCr 8.88TCr 8.22TCr 14TCr 9,60600Cr 15TCr 98TCr 38TCr 4,72300Cr 38TCr 37TCr 16,40700Cr | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 9.09TCr 12TCr 11TCr 9.74TCr 17TCr 11,39100Cr 17TCr 1,15800Cr 45TCr 5,60100Cr 45TCr 44TCr 19,45700Cr | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GSK plc
| 1 day | +0.34% | ||
| 1 week | -1.54% | ||
| Current month | +2.05% | ||
| 1 month | -0.26% | ||
| 3 months | -0.88% | ||
| 6 months | +5.81% | ||
| Current year | +5.23% |
| 1 week | 1,906 |  | 1,978.5 |
| 1 month | 1,805 | | 2,191 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 08/06 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 22/05 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 15/05 | Buy | Director | 2,301 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.23% | -1.54% | +36.85% | +34.72% | 10TCr | |
| +0.32% | -2.41% | +44.49% | +140.80% | 98TCr | |
| +1.27% | -1.85% | +54.41% | +39.65% | 56TCr | |
| +6.25% | +3.80% | +24.13% | +67.39% | 41TCr | |
| +1.63% | -1.93% | +23.33% | +16.35% | 31TCr | |
| +1.53% | +0.72% | +28.41% | +17.14% | 27TCr | |
| +1.54% | +0.05% | +26.76% | +33.56% | 27TCr | |
| +1.48% | +5.02% | -36.96% | -44.76% | 20TCr | |
| +2.11% | -1.66% | +19.14% | +50.10% | 19TCr | |
| +0.90% | +0.46% | +15.09% | +59.86% | 16TCr | |
| Average | +1.62% | -1.00% | +23.56% | +41.48% | 34.52TCr | |
| Weighted average by Cap. | +1.61% | -2.20% | +31.38% | +63.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.38TCr 4.48TCr 3.91TCr 3.62TCr 6.34TCr 4,23300Cr 6.39TCr 43TCr 17TCr 2,08100Cr 17TCr 16TCr 7,23000Cr | 3.55TCr 4.7TCr 4.11TCr 3.8TCr 6.66TCr 4,44400Cr 6.71TCr 45TCr 18TCr 2,18500Cr 18TCr 17TCr 7,59000Cr |
| Net income | 626.62Cr 830.62Cr 725.8Cr 671.36Cr 1.18TCr 78TCr 1.18TCr 7.98TCr 3.1TCr 39TCr 3.12TCr 3.05TCr 1,34100Cr | 666.92Cr 884.04Cr 772.48Cr 714.54Cr 1.25TCr 84TCr 1.26TCr 8.49TCr 3.3TCr 41TCr 3.32TCr 3.25TCr 1,42700Cr |
| Net Debt | 1.43TCr 1.89TCr 1.65TCr 1.53TCr 2.68TCr 1,78500Cr 2.7TCr 18TCr 7.06TCr 88TCr 7.09TCr 6.94TCr 3,04900Cr | 1.12TCr 1.48TCr 1.3TCr 1.2TCr 2.1TCr 1,40200Cr 2.12TCr 14TCr 5.54TCr 69TCr 5.57TCr 5.45TCr 2,39400Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 1,919.00 p | -0.29% | 1,28,173 |
| 22/26/22 | 1,924.50 p | -0.05% | 35,67,970 |
| 19/26/19 | 1,925.50 p | +0.13% | 1,51,21,490 |
| 18/26/18 | 1,923.00 p | -2.51% | 75,65,889 |
| 17/26/17 | 1,972.50 p | +1.15% | 47,13,671 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
